Inflammatory Bowel Diseases
Cure8 research brief
Why This Matters
For patients and clinicians facing steroid- and infliximab-refractory acute severe ulcerative colitis, upadacitinib may be a third-line medical option that can produce rapid symptom and CRP improvement and allow some patients to avoid or delay colectomy.
Who Should Pay Attention
Hospitalized adult patients with severe ulcerative colitis refractory to IV corticosteroids and infliximab; clinicians managing ASUC; IBD specialists considering JAK inhibitors as rescue therapy.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
In 50 patients from 11 centers, symptom scores and CRP improved rapidly (by week 1) and those improvements were generally maintained through week 48. About half of patients remained on upadacitinib at 48 weeks. Colectomy occurred in 22% overall (many early), and adverse events attributed to upadacitinib were reported in 24% and were mostly nonsevere.
How to read this: This is a retrospective, observational cohort rather than a randomized trial, so results describe outcomes in a selected clinical population (severe, treatment-refractory inpatients) and cannot prove causation. The abstract-level source supports short- and longer-term follow-up but does not replace randomized evidence.
Keep In Mind
This report is a multicenter retrospective cohort (abstract-level summary). It describes real-world outcomes but is not a randomized trial; early colectomies and selection of very refractory patients may influence generalizability. Safety events were mostly nonsevere in this cohort, but broader safety profiles of JAK inhibitors remain relevant.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationInflammatory Bowel Diseases
PublisherOxford University Press (OUP)
AuthorsNalan Gülşen Ünal, Oğuz Kağan Bakkaloğlu, Taylan Kav +22 more
Study typeJournal Article
Indexed viaCrossref
Source typeResearch paper
PublishedJul 22, 2026, 12:00 AM
Content availableJournal abstract
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
A Real-World Study of Upadacitinib in Anti-TNF Refractory Crohn's Disease - Dove Medical Press
This study looks at upadacitinib in people with Crohn’s disease who did not respond to anti-TNF drugs — a common and challenging clinical situation.
Sequential Biologic, Small-Molecule, and GLP-1 Analogue Therapy in Postcolectomy Enteritis With High Output Stoma.
People with ulcerative colitis who have had colectomy can rarely develop inflammation of the small intestine and high-output stomas that are hard to control.
Real-world outcomes of subcutaneous infliximab in a Middle Eastern inflammatory bowel disease cohort: a prospective study of switch and de novo treatment strategies.
Many patients and clinicians are interested in subcutaneous infliximab because it can be more convenient than IV infusions and may change drug exposure.